OXiGENE Inc (NASDAQ:OXGN), a biopharmaceutical company developing novel therapies for the treatment of cancer, provided an update on recent discussions with the U.S.
OXiGENE Inc (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that it has entered into definitive agreements with institutional investors …
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial results for the year ended December 31, 2014.
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel cancer therapeutics, announced that David Chaplin, Ph.
MLV analyst George Zavoico is out today with his second report this week on Oxigene (NASDAQ:OXGN), maintaining a Buy rating with a $6.50 price target, as Genentech …
In a research note published this morning, H.C.
In a research report released this morning, H.C.
After initiating coverage last week, MLV analyst George Zavoico is out today with his second report on Oxigene (NASDAQ:OXGN), maintaining a Buy rating with a $6.50 …
In a research report sent to investors, MLV analyst George Zavoico initiated Buy rating on Oxigene (NASDAQ:OXGN) with a $6.50 price target, which …
In a research report issued today, H.C.
